PATIENTS

AuroLase for the

Ablation of Prostate

Cancer Tissue

PATIENTS

AuroLase for the

Ablation of Prostate

Cancer Tissue

AuroLase Therapy for prostate disease is the first and only ultra-focal tissue ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation, and traditional focal therapies. The company is currently conducting a multi-site clinical trial for prostate disease.

Tumor Ablation using AuroLase Therapy

AuroLase® Therapy combines the unique physical and optical properties of AuroShell® particles with a near-infrared laser source to thermally destroy cancer tissue without significant damage to surrounding healthy tissue. Nanospectra’s proprietary AuroShells circulate freely in the blood stream and collect in the tumor. With state of the art imaging technology, the clinician accurately identifies the lesion and positions the optical fiber probe via targeted MRI Ultrasound fusion technology. The diseased tissue is ablated while sparing the surrounding tissue.

Performed on an outpatient basis, the AuroLase procedure results in significantly fewer side effects enabling the patient to return to a normal lifestyle within days versus weeks. In addition, patients lose no follow-on clinical options.

AuroShell particles are investigational at this current time and only available through designated FDA sanctioned clinical study sites.

PATIENT RESOURCES

 

I’d like more information on clinical trials